IRLAB Therapeutics AB (publ)
The answer first
Does IRLAB Therapeutics beat the market?
No, IRLAB Therapeutics has not beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 12% of Nordic stocks
- Quality43
- Value31
- Trend14
No. 157 of 195 in healthcare
Max for seven days
Follow IRLAB Therapeutics with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about IRLAB Therapeutics
Your first answer is free, no account needed.
Do you own IRLAB Therapeutics, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with IRLAB Therapeutics and a few more. Free, no card.
Super Stock+46.4%In short
- IRLAB Therapeutics has fallen 65.2% over the past year, including dividends.
- Overall, IRLAB Therapeutics ranks better than 12% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 96.6%. The price is 99.2% below its peak now.
What do analysts think of IRLAB Therapeutics?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 12% of Nordic stocks.
No. 157 of 195 in healthcare
Medium An average company: the accounts are neither especially strong nor weak.
No. 141 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity0.03
- Asset turnoverSales divided by everything the company owns0.44
- Return on equityProfit divided by equity−58.3%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 75 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equity1.3
- P/SPrice divided by sales1.6
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flownegative earnings
The ranking is built on P/E, P/B and P/S.
Low Headwind in the share price: it has done worse than most over the last year.
No. 145 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months−55.7%
- 6 months−38.6%
- 9 months−56.3%
- 12 months−65.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own IRLAB Therapeutics
2 funds we follow own IRLAB Therapeutics. The share is how much of the fund the stock makes up.
- Sweden2
From the funds' latest known holdings.
About IRLAB Therapeutics
IRLAB Therapeutics AB (publ) is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 31 employees.
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other central nervous system (CNS) disorders in the United States. The company develops Mesdopetam (IRL790), which has completed both a Phase IIb clinical trial for the treatment of levodopa-induced dyskinesias, and a Phase I clinical trial for the treatment of Parkinson's disease psychosis; Pirepemat (IRL752), which is in a Phase IIB clinical trial to reduce the risk of falling and falls in Parkinson's disease, and in a Phase IIA clinical trial for dementia in Parkinson's disease; and IRL757, which is in a Phase I clinical trial for the treatment of apathy in Parkinson's and other neurolog…


See the full analysis of IRLAB Therapeutics.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card